GlassScriptPhysician profile
John Dudley Cheape
NPI 1164505491
$2,197.55
in general payments reported to CMS, 2019-2025
13 companies · $33.33 in 2025
The $33.33 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.74 · 2020: $32.14 · 2021: $164 · 2022: $1,491 · 2023: $183 · 2024: $211 · 2025: $33.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,808.18 | 2020-2024 | Da Vinci Surgical System |
| Ethicon US, LLC | $76.47 | 2024 | Enseal, Harmonic, Echelon Flex |
| Pacira Pharmaceuticals Incorporated | $73.75 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.66 | 2019-2021 | |
| Axonics, INC. | $38.67 | 2023-2024 | Axonics |
| Tela Bio, INC. | $33.33 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Innovation Technologies INC | $32.33 | 2022 | |
| Solventum Corporation | $22.00 | 2024 | V.A.C. Dermatac, Activ.A.C. |
| Takeda Pharmaceuticals U.S.A., INC. | $18.62 | 2023 | Gattex |
| Baudax Bio INC. | $16.96 | 2021 | |
| La Jolla Pharmaceutical Company | $13.83 | 2023 | Xerava |
| Merck Sharp & Dohme LLC | $12.29 | 2019 | |
| Prescient Surgical | $7.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cheape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.